Barclays PLC Grows Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Barclays PLC boosted its holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 352.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 129,210 shares of the company’s stock after buying an additional 100,678 shares during the quarter. Barclays PLC owned 0.08% of Neumora Therapeutics worth $1,708,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of NMRA. State Street Corp grew its stake in shares of Neumora Therapeutics by 65.3% in the third quarter. State Street Corp now owns 1,790,707 shares of the company’s stock worth $23,655,000 after acquiring an additional 707,409 shares during the period. Geode Capital Management LLC boosted its holdings in Neumora Therapeutics by 54.0% in the third quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock worth $26,159,000 after purchasing an additional 694,385 shares during the last quarter. Callan Capital LLC grew its position in Neumora Therapeutics by 222.6% in the 2nd quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock worth $6,500,000 after purchasing an additional 456,207 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Neumora Therapeutics by 139.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock valued at $9,224,000 after buying an additional 406,891 shares during the last quarter. Finally, Auour Investments LLC bought a new position in shares of Neumora Therapeutics during the 3rd quarter valued at $3,302,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Wall Street Analyst Weigh In

NMRA has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Neumora Therapeutics in a report on Friday, January 3rd. Royal Bank of Canada downgraded Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price target for the company from $29.00 to $4.00 in a research note on Thursday, January 2nd. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a research note on Thursday, January 2nd. JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $18.00 to $15.00 in a report on Tuesday, November 5th. Finally, Bank of America reduced their target price on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a report on Monday, January 6th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Insiders Place Their Bets

In other news, Director Matthew K. Fust sold 14,049 shares of the company’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $17.03, for a total value of $239,254.47. Following the completion of the transaction, the director now owns 20,100 shares of the company’s stock, valued at $342,303. This represents a 41.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 26.40% of the stock is currently owned by company insiders.

Neumora Therapeutics Trading Down 6.8 %

Neumora Therapeutics stock opened at $2.21 on Friday. Neumora Therapeutics, Inc. has a 12-month low of $1.83 and a 12-month high of $21.00. The firm has a market capitalization of $357.05 million, a price-to-earnings ratio of -1.18 and a beta of 2.71. The firm has a 50 day moving average of $9.54 and a 200 day moving average of $11.26.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same period in the previous year, the firm earned ($1.14) EPS. On average, analysts predict that Neumora Therapeutics, Inc. will post -1.61 EPS for the current year.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.